- Breast Cancer
- Blood cancer
- Liver Cancer
- Brain cancer
- Colorectal Cancer
- Others
Antibody Combination Therapy Market size was valued at USD 236.2 billion in 2023 and is poised to grow at a CAGR of 12.8% from 2024-2030. Foods that are subjected to technological modifications either for protection or for changing over into prepared-to-utilize/eat nourishments, disposing of relentless family unit strategies, are called antibody combination therapy. A portion of the cases is processed blends, dried-out nourishments, pasta items, canned food, confectioneries, pastry shops, dairy items, and breakfast nourishments. Manufacture of Antibody Combination Therapy requires innovative application and apparatus, and thus, Antibody Combination Therapy is costly. Organizations are embracing different techniques, for example, an extension of product features to maintain the powerfully developing antibodies advertise.
The worldwide Antibody Combination Therapy Market is relied upon to witness great development over the conjecture time frame. However, the mind-boggling expense of treatment and symptoms related to antibody treatment can upset the development of the worldwide Antibody Combination Therapy Market. There has been an expansion in R&D exercises by numerous pharmaceutical and biotechnology organizations to create progressed biologics including monoclonal antibodies. Spotlight on R&D is a basic system to drive long-haul development of the organization. A few pharmaceutical and biotechnology organizations are experiencing associations and joint efforts to pick up initiatives in the division. For example,
Antibody Combination Therapy Market Key Developments:
- In June 2016, Novartis and Xencor Inc., went into a vital joint effort and authorizing assention. The significant organizations are embraced different methodologies activities, for example, new product advancement, mergers and acquisitions, joint efforts, and provincial extension for serving the neglected needs of their clients.
Antibody Combination Therapy Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
12.8%
Largest Market
North America
Fastest Growing Market
Asia-Pacific
Antibody Combination Therapy Market Dynamics
Worldwide Antibody Combination Therapy Market is principally determined by components, for example, consistent dispatch of creative items, high appropriation rate of helpful antibodies in cost-touchy markets, brisk endorsement by administrative specialists for leap forward treatments, ascend in interminable diseases attributable to populace move and expanding life span, accessibility of economical biosimilar counter acting agent therapeutics, and reception of symptomatic antibodies.
North-America Got Significant Share
Antibody Combination Therapy Market Regional Analysis
North America was the biggest income creating locale of the Antibody Combination Therapy market. This locale is relied upon to keep up its situation amid the gauge time frame in light of the nearness of a few driving biopharmaceuticals and biotechnology organizations in this region. Asia Pacific is anticipated to be the quickest developing portion over the investigation time frame, because of quickly blasting biotechnology industry and relatively less stringent controls for biologics advancement in APAC area.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Antibody Combination Therapy Market Segmentation
By Therapeutic Type
By Mode of Administration
- Parenteral
- Enteral
- Others
By Type
- Murine Antibodies,
- Humanized Antibodies,
- Chimeric Antibodies
By Distribution Channel
- Hospital Pharmacy,
- Retail Pharmacy, and
- Online Pharmacy
Frequently Asked Questions
The antibody combination therapy market size was valued at USD 231 billion in 2023
The antibody combination therapy market key players are: Merck & Co. Inc. (U.S.) Hoffmann-La Roche AG (Switzerland) Spectrum Pharmaceuticals U.S.) Eli Lilly and Company (U.S.) Amgen Inc. (U.S.) Bristol-Meyer Squibb (U.S.) Sanofi S.A. (France) AstraZeneca plc (U.S.)
The antibody combination therapy market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1. Executive Summary |
| 2. Global Antibody Combination Therapy Market Introduction |
| 2.1.Global Antibody Combination Therapy Market - Taxonomy |
| 2.2.Global Antibody Combination Therapy Market - Definitions |
| 2.2.1.Therapeutic Type |
| 2.2.2.Mode of Administration |
| 2.2.3.Type |
| 2.2.4.Distribution Channel |
| 2.2.5.Region |
| 3.Global Antibody Combination Therapy Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Antibody Combination Therapy Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Antibody Combination Therapy Market By Therapeutic Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Breast Cancer |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Blood cancer |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Liver Cancer |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Brain cancer |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Colorectal Cancer |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6.Global Antibody Combination Therapy Market By Mode of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Parenteral |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Enteral |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Antibody Combination Therapy Market By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Murine Antibodies, |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Humanized Antibodies, |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Chimeric Antibodies |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Antibody Combination Therapy Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Hospital Pharmacy, |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Retail Pharmacy, and |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Online Pharmacy |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9.Global Antibody Combination Therapy Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Antibody Combination Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Therapeutic Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Breast Cancer |
| 10.1.2.Blood cancer |
| 10.1.3.Liver Cancer |
| 10.1.4.Brain cancer |
| 10.1.5.Colorectal Cancer |
| 10.1.6.Others |
| 10.2. Mode of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Parenteral |
| 10.2.2.Enteral |
| 10.2.3.Others |
| 10.3. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Murine Antibodies, |
| 10.3.2.Humanized Antibodies, |
| 10.3.3.Chimeric Antibodies |
| 10.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospital Pharmacy, |
| 10.4.2.Retail Pharmacy, and |
| 10.4.3.Online Pharmacy |
| 10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Antibody Combination Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Therapeutic Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Breast Cancer |
| 11.1.2.Blood cancer |
| 11.1.3.Liver Cancer |
| 11.1.4.Brain cancer |
| 11.1.5.Colorectal Cancer |
| 11.1.6.Others |
| 11.2. Mode of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Parenteral |
| 11.2.2.Enteral |
| 11.2.3.Others |
| 11.3. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Murine Antibodies, |
| 11.3.2.Humanized Antibodies, |
| 11.3.3.Chimeric Antibodies |
| 11.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospital Pharmacy, |
| 11.4.2.Retail Pharmacy, and |
| 11.4.3.Online Pharmacy |
| 11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 11.5.6.Rest of EU |
| 12. Asia Pacific (APAC) Antibody Combination Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Therapeutic Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Breast Cancer |
| 12.1.2.Blood cancer |
| 12.1.3.Liver Cancer |
| 12.1.4.Brain cancer |
| 12.1.5.Colorectal Cancer |
| 12.1.6.Others |
| 12.2. Mode of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Parenteral |
| 12.2.2.Enteral |
| 12.2.3.Others |
| 12.3. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Murine Antibodies, |
| 12.3.2.Humanized Antibodies, |
| 12.3.3.Chimeric Antibodies |
| 12.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospital Pharmacy, |
| 12.4.2.Retail Pharmacy, and |
| 12.4.3.Online Pharmacy |
| 12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Antibody Combination Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Therapeutic Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Breast Cancer |
| 13.1.2.Blood cancer |
| 13.1.3.Liver Cancer |
| 13.1.4.Brain cancer |
| 13.1.5.Colorectal Cancer |
| 13.1.6.Others |
| 13.2. Mode of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Parenteral |
| 13.2.2.Enteral |
| 13.2.3.Others |
| 13.3. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Murine Antibodies, |
| 13.3.2.Humanized Antibodies, |
| 13.3.3.Chimeric Antibodies |
| 13.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospital Pharmacy, |
| 13.4.2.Retail Pharmacy, and |
| 13.4.3.Online Pharmacy |
| 13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Antibody Combination Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 14.1. Therapeutic Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Breast Cancer |
| 14.1.2.Blood cancer |
| 14.1.3.Liver Cancer |
| 14.1.4.Brain cancer |
| 14.1.5.Colorectal Cancer |
| 14.1.6.Others |
| 14.2. Mode of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Parenteral |
| 14.2.2.Enteral |
| 14.2.3.Others |
| 14.3. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Murine Antibodies, |
| 14.3.2.Humanized Antibodies, |
| 14.3.3.Chimeric Antibodies |
| 14.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospital Pharmacy, |
| 14.4.2.Retail Pharmacy, and |
| 14.4.3.Online Pharmacy |
| 14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Merck & Co. Inc. (U.S.) |
| 15.2.2.Hoffmann-La Roche AG (Switzerland) |
| 15.2.3.Spectrum Pharmaceuticals U.S.) |
| 15.2.4.Eli Lilly and Company (U.S.) |
| 15.2.5.Amgen Inc. (U.S.) |
| 15.2.6.Bristol-Meyer Squibb (U.S.) |
| 15.2.7.Sanofi S.A. (France) |
| 15.2.8.AstraZeneca plc (U.S.) |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
- Merck & Co. Inc. (U.S.)
- Hoffmann-La Roche AG (Switzerland)
- Spectrum Pharmaceuticals U.S.)
- Eli Lilly and Company (U.S.)
- Amgen Inc. (U.S.)
- Bristol-Meyer Squibb (U.S.)
- Sanofi S.A. (France)
- AstraZeneca plc (U.S.)